Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 12/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | F7 | P08709 | 2/20 | 0.36 |
| ▸ | F3 | P13726 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.36 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.36 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1715340 | 1.00 | CYSLTR2 (0.43) | CYSLTR2CYSLTR1IDO1MMP2F7 | |
| SCHEMBL11127905 | 0.88 | CYSLTR2 (0.44) | CYSLTR2CYSLTR1MMP2F7F3 | |
| Ether SCHEMBL11047230 | 0.84 | CYSLTR2 (0.42) | CYSLTR2CYSLTR1MMP2F7F3 | |
| SCHEMBL27875985 | 0.81 | F7 (0.49) | CYSLTR2CYSLTR1MMP2F7F3 | |
| SCHEMBL10482163 | 0.80 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1MMP2F7F3 | |
| SCHEMBL10617350 | 0.80 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1MMP2F7F3 | |
| SCHEMBL10482169 | 0.80 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1MMP2F7F3 | |
| SCHEMBL10383342 | 0.80 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1MMP2F7F3 | |
| SCHEMBL6434846 | 0.80 | BACE1 (0.51) | CYSLTR2CYSLTR1 | |
| SCHEMBL6436782 | 0.80 | BACE1 (0.51) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | claimed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | CYSLTR2 2916/4885CYSLTR1 2115/4885IDO1 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.